[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500264":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":36,"centralContacts":41,"locations":47,"responsibleParty":62,"collaborators":23,"id":64,"slug":23,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":23,"enrollmentInfo":73,"targetDuration":23,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":49,"whyStopped":23,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Tomsk National Research Medical Center of the Russian Academy of Sciences","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: 1","ACTIVE_COMPARATOR","Drug: Ferinject ® (Ferric carboxymaltose)",[13],"Drug: Ferinject",{"label":15,"type":6,"description":16,"interventionNames":17},"Comparison Group: 2","Diet therapy, without drug therapy",[18],"Other: Diet therapy",{"label":20,"type":21,"description":22,"interventionNames":23},"Control Group: 3","NO_INTERVENTION","Without therapy",null,[25,32],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Ferinject","The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.",[9],[31],"Ferric carboxymaltose",{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":23},"Diet therapy","Patients will receive diet therapy to correct latent iron deficiency",[15],[37],{"name":38,"affiliation":39,"role":40},"Alla A. Garganeeva, M.D.","Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":23,"email":46},"Olga V. Tukish, Ph.D.","CONTACT","+79069476343","olgatukish@yandex.ru",[48],{"facility":39,"status":49,"city":50,"state":23,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Tomsk","634012","Russia",{"type":54,"coordinates":55},"Point",[56,57],84.98216,56.50049,{"lat":57,"lon":56},[60],{"name":43,"role":44,"phone":61,"phoneExt":23,"email":46},"89069476343",{"type":63,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100500264",false,"NCT05793996","The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)","Study of the Prevalence of Iron Deficiency Among Hospitalized Patients With HFpEF and the Impact of Ferinject® on Indicators of Quality of Life, Functional Status in Patients With Iron Deficiency","ID-HFpEF","Inclusion Criteria:\n\n* Signed informed consent to participate in the study;\n* In New York Heart Association (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF);\n* Left ventricular ejection fraction (LVEF) ≥50%; objective signs of structural and\u002For functional disorders of the heart consistent with the presence of LV diastolic dysfunction\u002Fincreased LV filling pressure, including elevated levels of natriuretic peptide;\n* Screening ferritin below 100 µg\u002FL, or below 300 µg\u002FL when transferrin saturation (TSAT) is below 20%;\n* Screening haemoglobin (Hb) at the time of switching on ( 90-150 g\u002Fl).\n\nExclusion Criteria:\n\n* Uncontrolled arterial hypertension;\n* Аnemia not related to iron deficiency;\n* Аnemia with a hemoglobin level of less than 90 g\u002Fl;\n* Less than 1 year after acute myocardial infarction;\n* Less than 1 year after acute cerebral circulation disorder;\n* Less than 1 year after surgical interventions, including non-cardiac operations and myocardial revascularization (coronary bypass surgery, coronary artery stenting), operations for valvular pathology;\n* Chronic alcoholism (including alcoholic heart disease), mental disorders;\n* Severe hepatic (increased transaminase levels above the upper three limits of normal) and renal insufficiency (glomerular filtration rate less than 15 ml\u002Fmin\u002F1.73 m2);\n* Known active infection, clinically significant bleeding, active malignancy;\n* Severe autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc.);\n* Severe bronchial asthma, COPD in the acute stage;\n* Allergic reactions to medications in the anamnesis, eczema, atopic allergic reaction;\n* Blood transfusions and taking erythropoiesis-stimulating drugs during the previous three months.","ALL","18 Years",{"count":74,"type":75},100,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","Observational cohort randomized controlled study to study the influence of correction of ID by intravenous injection of ferric carboxymaltose (Ferinject®) on quality of life indicators, functional status in a cohort of patients with HFpEF.",[81,82],"Chronic Heart Failure","Iron Deficiency, Latent",[84,85,86,27],"HFpEF","iron deficiency","ferric carboxymaltose","2026-06-23",{"date":89,"type":90},"2026-06-24","ACTUAL",{"date":92,"type":90},"2023-04-28",{"date":94,"type":75},"2026-12",{"name":5,"class":6},1]